<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A07B&quot;,&quot;href&quot;:&quot;atc/A07B.md&quot;},{&quot;label&quot;:&quot;kaolin&quot;}]"></div>

# kaolin

- **generic name:** kaolin
- **ATC codes:** `A07BC02`
- **DrugBank:** [DB01575](https://go.drugbank.com/drugs/DB01575) · **PubChem:** [CID 92024769](https://pubchem.ncbi.nlm.nih.gov/compound/92024769)
- **molar mass:** 258.156 g/mol (Al2H4O9Si2) — DrugBank
- **groups:** approved

## About

Kaolin is an intestinal adsorbent used as an antidiarrhoeal medicine to treat diarrhoea. It is an approved medication, classified for the alimentary tract as an intestinal adsorbent, and is used as an antidiarrhoeal agent.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q20817222](https://www.wikidata.org/wiki/Q20817222) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 18:54 | 6:41 | 0/0/0 | 0/0/0 | 0/0/0 | 218,318/11,085 | ollama / qwen3.8:27b-mtp-q8_0 | 12 | 3/15 | 12/0 | 0 |

## popPK records

_not available_

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 100 matched, 71 returned
- **screened:** 0  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_1 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Moynihan_2017.pdf` | Moynihan K et al., Coagulation monitoring correlation with…, Perfusion (2017) | pd | 5 | [10.1177/0267659117720494](https://doi.org/10.1177/0267659117720494) | [28693359](https://www.ncbi.nlm.nih.gov/pubmed/28693359) | metadata signals extractable PD data (pharmacodynamicmodel) |

<sub>queue written 2026-10-04T18:50:08.339226+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Adoley_2026 | irrelevant | 0 | 0 | The paper is a pharmaceutical formulation study where kaolin is used as an excipient (absorbent), not as the subject drug for pharmacokinetic evaluation. |
| PD | Adoley_2026 | not_relevant | 0 | 0 | The paper reports IC50 values for plant extracts (Azadirachta indica and Khaya senegalensis) but does not report any pharmacodynamic or exposure-response relationship for kaolin, which is used only as an excipient. |
| popPK | Agersø_2012 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of turoctocog alfa and N8-GP in dogs, not kaolin. |
| PD | Agersø_2012 | not_relevant | 0 | 0 | The paper reports PK and PD profiles for turoctocog alfa and N8-GP, not kaolin. |
| popPK | Albert_1978 | irrelevant | 0 | 0 | The study evaluates the pharmacokinetics of clindamycin in the presence of kaolin-pectin, not the pharmacokinetics of kaolin itself. |
| popPK | Alonso-Castro_2015 | irrelevant | 0 | 0 | The study investigates the pharmacological effects of kramecyne, and kaolin is only used as an irritant in the arthritis model, not as the subject drug for PK analysis. |
| popPK | Anderson_2020 | irrelevant | 0 | 0 | The paper is an ecotoxicology study on amphipods and does not report pharmacokinetic parameters for kaolin. |
| popPK | Attia_2004 | irrelevant | 0 | 0 | The study focuses on piroxicam pharmacokinetics/permeation, and kaolin is used only as an irritant to induce paw edema in a pharmacodynamic model, not as the subject drug for PK analysis. |
| PD | Attia_2004 | not_relevant | 1 | 0 | The paper uses kaolin as an inflammatory stimulus (kaolin-induced paw oedema) to test piroxicam, rather than reporting a pharmacodynamic relationship for kaolin itself. |
| popPK | Bloch_2006 | irrelevant | 0 | 0 | The study investigates the pathophysiology of hydrocephalus in mice using kaolin as an irritant agent, not the pharmacokinetics of kaolin itself. |
| popPK | Branson_2011 | irrelevant | 0 | 0 | no_text gate: only 39 chars of text extracted (&lt; 400) |
| PD | Branson_2011 | not_relevant | 0 | 0 | The paper discusses oxygen toxicity and does not contain any pharmacodynamic or exposure-response data for kaolin. |
| popPK | Bursi_2017 | irrelevant | 0 | 0 | The study evaluates the pharmacokinetics of lidocaine, not kaolin. |
| PD | Bursi_2017 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic (PK) model for lidocaine, but it does not report any pharmacodynamic (PD) or exposure-response relationship, nor does it provide numeric PD parameters. |
| popPK | Chelle_2021 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of octocog alfa (a hemophilia treatment), not kaolin. |
| PD | Chelle_2021 | not_relevant | 0 | 0 | The paper focuses exclusively on the qualification of population pharmacokinetic (PK) models for octocog alfa (Kovaltry) and does not report any pharmacodynamic (PD) or exposure-response relationships. |
| popPK | Dawood_2019 | irrelevant | 0 | 0 | The paper is an environmental engineering study on dye adsorption using kaolin as an adsorbent, not a pharmacokinetic study of kaolin as a drug. |
| PD | Dawood_2019 | not_relevant | 0 | 0 | The paper describes environmental engineering adsorption kinetics (breakthrough curves) for dye removal, not pharmacodynamic drug-response relationships. |
| popPK | Eaton_2022 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of dabigatran in rabbits, where kaolin is used only as a reagent for thromboelastography (rTEG) and is not the subject drug. |
| popPK | Engel_2014 | irrelevant | 0 | 0 | The paper is a mechanistic study of Factor XII autoactivation where kaolin is used only as a non-physiological activating surface/comparator, not as a drug subject to pharmacokinetic analysis. |
| PD | Engel_2014 | not_relevant | 0 | 0 | The paper investigates the biochemical mechanism of Factor XII activation by polyphosphate and does not report any pharmacodynamic or exposure-response relationship for kaolin. |
| popPK | Erkinaro_2022 | irrelevant | 0 | 0 | The paper discusses kaolin as a reagent for activated clotting time (ACT) testing in coagulation monitoring, not as a drug subject to pharmacokinetic analysis. |
| PD | Erkinaro_2022 | not_relevant | 3 | 1 | The paper mentions an in vitro dose-response test for heparin in FXII-deficient blood but does not provide numeric PD parameters or a quantitative curve for kaolin itself, which is only described as a qualitative activator causing prolonged baseline ACT. |
| popPK | Fernández-Bello_2017 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of recombinant activated factor VII (rFVIIa), using kaolin only as a reagent/activator for thromboelastography, not as the subject drug. |
| PD | Fernández-Bello_2017 | not_relevant | 2 | 1 | The paper describes a qualitative dose-dependent effect of rFVIIa on TEG/TGA assays but does not provide numeric PD parameters (e.g., Emax, EC50) or a quantitative exposure-response model. |
| popPK | Fischer_2022 | irrelevant | 0 | 0 | The paper is an ecotoxicology study on copper oxide nanoparticles in soil, where kaolin is used as a clay component, not as a drug subject for pharmacokinetic analysis. |
| PD | Fischer_2022 | not_relevant | 0 | 0 | The paper studies the toxicity of copper oxide nanoparticles in soil, not the pharmacodynamics of kaolin as a drug. |
| popPK | Fosse_2011 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of ketoprofen, using kaolin only as an agent to induce inflammation for pharmacodynamic evaluation. |
| popPK | Franchi_2015 | irrelevant | 0 | 0 | The paper is a pharmacodynamic study of vitamin K antagonists where kaolin is used only as a reagent in the thromboelastography assay, not as the subject drug for PK analysis. |
| PD | Franchi_2015 | not_relevant | 0 | 0 | The paper investigates the correlation between TEG parameters and INR for Vitamin K antagonists; kaolin is mentioned only as a reagent in the TEG assay, and no pharmacodynamic parameters (Emax, EC50, etc.) are reported for kaolin itself. |
| popPK | Giraudel_2005 | irrelevant | 0 | 0 | Kaolin is used as an agent to induce inflammation in the model, not as the subject drug for pharmacokinetic analysis (the subject drug is meloxicam). |
| popPK | Giraudel_2009 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of robenacoxib, using kaolin only as an agent to induce inflammation (kaolin-induced paw inflammation model), not as the subject drug. |
| popPK | Gordon_2015 | irrelevant | 0 | 0 | The paper is an ecotoxicology study on aquatic organisms, not a pharmacokinetic study of kaolin in a biological host. |
| popPK | Guzzetta_2006 | irrelevant | 0 | 0 | The paper studies heparin pharmacodynamics and uses kaolin only as an activator for the activated clotting time (ACT) test, not as a subject drug for pharmacokinetic analysis. |
| PD | Guzzetta_2006 | not_relevant | 3 | 0 | The paper mentions a "heparin dose-response relationship" was calculated, but the provided text does not contain the numeric parameters, curve data, or specific values required to extract a PD relationship. |
| popPK | Han_2006 | irrelevant | 0 | 0 | The paper is a neurophysiological study using kaolin as an irritant to induce arthritis for pain modeling, not a pharmacokinetic study of kaolin. |
| popPK | Ichikawa_2017 | irrelevant | 0 | 0 | The study focuses on heparin pharmacodynamics and dosing during cardiac surgery, using kaolin only as a reagent for the activated clotting time (ACT) assay, not as the subject drug for PK analysis. |
| PD | Ichikawa_2017 | not_relevant | 2 | 1 | The paper analyzes the variability and accuracy of the heparin dose-response slope (HDR) in predicting ACT, but it does not report a specific pharmacodynamic model (e.g., Emax, EC50) or numeric PD parameters for kaolin itself; it treats the HDR slope as a variable to be critiqued rather than a PD parameter to be estimated. |
| popPK | Jeunesse_2011 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for meloxicam, while kaolin is used only as an inert agent to induce inflammation (a model stimulus), not as the subject drug. |
| popPK | Jeunesse_2013 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of cimicoxib, using kaolin only as an agent to induce inflammation in a PK/PD model, not as the subject drug. |
| PGx | Jeunesse_2013 | not_relevant | 0 | 0 | The paper studies the pharmacokinetics of the drug cimicoxib, not kaolin, and the phenotypic differences (PM/EM) are not linked to a specific gene variant. |
| PGx | Kanupriya_2025 | not_relevant | 0 | 0 | The paper studies the effect of kaolin spray on dragon fruit plants, not the pharmacokinetics or pharmacodynamics of kaolin in humans. |
| popPK | Knudsen_2011 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of recombinant canine FVIIa, using kaolin only as a reagent for thromboelastography, not as the subject drug. |
| PD | Knudsen_2011 | not_relevant | 2 | 1 | The study reports qualitative improvements in kaolin-activated thromboelastography and PK parameters, but does not provide numeric PD parameters (e.g., Emax, EC50) or a quantitative concentration-effect relationship. |
| popPK | Levionnois_2018 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for flunixin meglumine, using kaolin only as an agent to induce inflammation, not as the subject drug. |
| PGx | Liu_2002 | not_relevant | 0 | 0 | The paper studies the pharmacokinetics of recombinant hirudin variant-2 in rhesus monkeys and does not report any pharmacogenomic effects or gene variants. |
| popPK | Maas_2018 | irrelevant | 0 | 0 | The study investigates the pharmacodynamics of dabigatran, and kaolin is only mentioned as a reagent in the aPTT assay, not as the subject drug. |
| popPK | Mackie_1992 | irrelevant | 0 | 0 | The paper investigates protease interference in protein C assays using kaolin as an activator, not as a subject drug for pharmacokinetic analysis. |
| PD | Mackie_1992 | not_relevant | 0 | 0 | The paper investigates protease interference in protein C assays using kaolin as an activator, but does not report a pharmacodynamic exposure-response or dose-response relationship for kaolin itself. |
| popPK | Mast_1995 | irrelevant | 0 | 0 | The paper is a chronic inhalation toxicity study reporting lung burdens and histopathology, not a pharmacokinetic study with quantitative disposition parameters (CL, V, etc.) for kaolin. |
| PD | Mast_1995 | not_relevant | 3 | 2 | The paper reports a chronic inhalation toxicity study with qualitative dose-response observations (e.g., lung burden, lesion severity) but does not provide a pharmacodynamic model or numeric PD parameters (Emax, EC50, etc.) for a drug effect. |
| popPK | Matulionis_1988 | irrelevant | 0 | 0 | The study is a toxicological/morphological investigation of lung tissue in mice and does not report any pharmacokinetic parameters for kaolin. |
| PD | Matulionis_1988 | not_relevant | 2 | 1 | The paper describes qualitative dose-response trends in a murine model but does not provide numeric PD parameters, concentration-effect curves, or a formal PK/PD model. |
| popPK | Mehendale_2005 | irrelevant | 0 | 0 | Kaolin is used as a diagnostic agent (pica model) to measure emetic response, not as the subject drug for pharmacokinetic analysis. |
| popPK | Melø_2011 | irrelevant | 0 | 0 | The study uses kaolin as a vehicle to induce hydrocephalus in rats and measures cerebral metabolic rates (TCA cycle), not the pharmacokinetic parameters of kaolin itself. |
| popPK | Mika_2021 | irrelevant | 0 | 0 | Kaolin is used only as a diagnostic agent to monitor gastrointestinal disturbances, not as the subject drug for pharmacokinetic analysis. |
| PD | Mika_2021 | not_relevant | 0 | 0 | The paper studies histamine H3 receptor ligands (KSK-59 and KSK-73), not kaolin; kaolin is only used as a behavioral marker for pica/nausea in a separate experiment without dose-response analysis. |
| popPK | Miles_2021 | irrelevant | 0 | 0 | The study focuses on protamine dosing and heparin clearance, using kaolin only as a reagent for thromboelastography (TEG) measurements, not as the subject drug for pharmacokinetic analysis. |
| popPK | Moynihan_2017 | irrelevant | 0 | 0 | no_text gate: only 93 chars of text extracted (&lt; 400) |
| PD | Moynihan_2017 | not_relevant | 0 | 0 | The paper focuses on heparin dosing and coagulation monitoring in pediatric ECMO, not kaolin, and does not report a kaolin exposure-response relationship. |
| popPK | Mueck_2013 | irrelevant | 0 | 0 | The paper discusses the pharmacokinetics of rivaroxaban, dabigatran, and apixaban, not kaolin. |
| PD | Mueck_2013 | not_relevant | 2 | 0 | The paper is a review that qualitatively describes the dose-dependent pharmacodynamic effects of rivaroxaban (Factor Xa inhibition) but does not provide specific numeric PD parameters (e.g., Emax, IC50) or extractable concentration-effect curves. |
| popPK | OGrady_1984 | irrelevant | 0 | 0 | The paper studies prostacyclin analogues and uses kaolin only as a reagent for clotting time assays, not as the subject drug for pharmacokinetic analysis. |
| popPK | Ranucci_2004 | irrelevant | 0 | 0 | The study focuses on the pharmacodynamic effect of gabexate mesilate on heparin responsiveness, using kaolin only as a reagent for the clotting time assay, not as the subject drug for PK analysis. |
| popPK | Rollini_2014 | irrelevant | 0 | 0 | The study is a pharmacodynamic assessment of antiplatelet drugs (aspirin/clopidogrel) where kaolin is used only as an activator in thromboelastography, not as the subject drug for PK analysis. |
| PD | Rollini_2014 | not_relevant | 1 | 0 | The paper reports qualitative differences in platelet reactivity between smoking groups on aspirin vs. clopidogrel, but does not provide numeric PD parameters (e.g., Emax, EC50) or an exposure-response curve for kaolin. |
| popPK | Saleem_2000 | irrelevant | 0 | 0 | The paper studies the effect of epsilon-aminocaproic acid on coagulation assays where kaolin is used as an activator, not as a subject drug for pharmacokinetic analysis. |
| PD | Saleem_2000 | not_relevant | 0 | 0 | The paper investigates the effect of epsilon-aminocaproic acid on point-of-care coagulation assays (HemoSTATUS and heparin dose response), not the pharmacodynamic relationship of kaolin itself; no PD parameters for kaolin are reported. |
| popPK | Salinas-Sánchez_2017 | irrelevant | 0 | 0 | The paper studies the anti-inflammatory activity of a plant extract in a kaolin/carrageenan arthritis model, where kaolin is used as an inflammatory agent, not as the subject drug for pharmacokinetic analysis. |
| popPK | Shi_2011 | irrelevant | 0 | 0 | The study is an in vitro assay validation where kaolin is used as a reagent, not as the subject drug for pharmacokinetic analysis. |
| popPK | Stocker_1988 | irrelevant | 0 | 0 | The paper discusses kaolin as a contact activator in a coagulation assay, not as a drug subject to pharmacokinetic analysis. |
| PD | Stocker_1988 | not_relevant | 1 | 0 | The text only provides a qualitative ranking of contact activators (kaolin &gt; ellagic acid &gt; sulfatide) regarding Protein C dose-response sensitivity, without reporting any numeric PD parameters or concentration-effect curves for kaolin. |
| popPK | Storm_2016 | irrelevant | 0 | 0 | The paper is a toxicological study on the efficacy of kaolin as a co-formulant for fungal biopesticides against insects, not a pharmacokinetic study. |
| popPK | Viuff_2010 | irrelevant | 0 | 0 | Kaolin is used as a reagent for thrombelastography (TEG) assays, not as a subject drug for pharmacokinetic analysis. |
| popPK | Yu_2002 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment using kaolin as an inflammatory agent to induce arthritis, not a pharmacokinetic study of kaolin. |
| PD | Yu_2002 | not_relevant | 0 | 0 | The paper describes behavioral pain indices in an arthritis model and mentions a qualitative dose-response for morphine, but it does not report any pharmacodynamic parameters or exposure-response relationship for kaolin. |
| popPK | Zhang_2012 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of bivalirudin, not kaolin (which is only mentioned as a reagent in the ACT assay). |
| popPK | unknown_2015 | irrelevant | 0 | 0 | no_text gate: only 106 chars of text extracted (&lt; 400) |
| PD | unknown_2015 | not_relevant | 0 | 0 | The provided text is only a header for a conference abstract collection and contains no specific data, analysis, or PD parameters for kaolin. |
| popPK | unknown_2018 | irrelevant | 0 | 0 | no_text gate: only 83 chars of text extracted (&lt; 400) |
| PD | unknown_2018 | not_relevant | 0 | 0 | The provided text is only a conference header and contains no study data, results, or pharmacodynamic parameters for kaolin. |
| popPK | unknown_2018_2 | irrelevant | 0 | 0 | no_text gate: only 52 chars of text extracted (&lt; 400) |
| PD | unknown_2018_2 | not_relevant | 0 | 0 | The provided text is only a conference header and contains no data, analysis, or mention of kaolin or pharmacodynamics. |
| popPK | unknown_2019 | irrelevant | 0 | 0 | no_text gate: only 65 chars of text extracted (&lt; 400) |
| PD | unknown_2019 | not_relevant | 0 | 0 | The provided text is only a conference header and contains no data, analysis, or mention of kaolin or pharmacodynamics. |
| popPK | unknown_2023 | irrelevant | 0 | 0 | no_text gate: only 16 chars of text extracted (&lt; 400) |
| PD | unknown_2023 | not_relevant | 0 | 0 | The provided text is only a conference title and contains no data, analysis, or mention of kaolin or pharmacodynamics. |
| popPK | van_2025 | irrelevant | 0 | 0 | The paper is an ecotoxicology study on earthworms using kaolin as a soil component, not a pharmacokinetic study of kaolin as a drug. |
| popPK | Østergaard_2011 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of PEGylated Factor IX (a hemophilia treatment), not the drug kaolin. |
| PD | Østergaard_2011 | not_relevant | 0 | 0 | The paper describes a PEGylated Factor IX product and reports PK half-life and qualitative efficacy, but does not report a concentration-effect or dose-response relationship with numeric PD parameters. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
